Recent Updates
Recently added Catalysts

GSK1265744 Na Salt

Phase 1

Infections, Human Immunodeficiency Virus and Hepatitis | Small molecule | Infectious Disease |GSK plc|Last Updated: Aug 12, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment18
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01648257Relative Bioavailability Study of GSK1265744 FormulationsPHASE1 COMPLETED 18Aug 1, 2012Nov 1, 2012Aug 12, 20161 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Composite of PK parameters following single oral dose administration of GSK1265744
For 168 hours post dose (36 days)

Plasma GSK1265744 PK parameters: area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time AUC(0-infinity); AUC from time zero to time t, AUC(0-t), and maximum observed concentration, Cmax.

Secondary Endpoints
Composite of PK parameters following single oral dose administration of GSK1265744
For 168 hours post each dose of GSK1265744 (36 days)
Safety and tolerability as assessed by the collection of adverse events
50 days
Safety and tolerability as assessed by change from baseline in clinical laboratory tests
50 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GSK1265744 Na Salt TabletsEXPERIMENTALSubjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
GSK1265744 Free Acid Nanomilled CapsulesEXPERIMENTALSubjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
GSK1265744 Free Acid Micronized CapsulesEXPERIMENTALSubjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
Interventions
NameTypeDescription
GSK1265744 Na Salt TabletsDRUGEach tablet contains 30 mg of GSK1265744 sodium salt and excipients.
GSK1265744 Free Acid Nanomilled CapsulesDRUGEach capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
GSK1265744 Free Acid Micronized CapsulesDRUGEach capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin =\< 1.5x upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Healthy as determined by a responsible and experienced physician, bas...

Countries:United States
Unlock Eligibility Criteria